Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) Enterprise Value (2020 - 2025)

Mirum Pharmaceuticals has reported Enterprise Value over the past 6 years, most recently at -$383.3 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$383.3 million for Q4 2025, down 36.75% from a year ago — trailing twelve months through Dec 2025 was -$383.3 million (down 36.75% YoY), and the annual figure for FY2025 was -$383.3 million, down 36.75%.
  • Enterprise Value for Q4 2025 was -$383.3 million at Mirum Pharmaceuticals, down from -$375.5 million in the prior quarter.
  • Over the last five years, Enterprise Value for MIRM hit a ceiling of -$132.1 million in Q1 2023 and a floor of -$383.3 million in Q4 2025.
  • Median Enterprise Value over the past 5 years was -$290.5 million (2022), compared with a mean of -$289.3 million.
  • Biggest five-year swings in Enterprise Value: surged 60.4% in 2023 and later plummeted 129.3% in 2024.
  • Mirum Pharmaceuticals' Enterprise Value stood at -$256.5 million in 2021, then grew by 1.88% to -$251.7 million in 2022, then decreased by 13.75% to -$286.3 million in 2023, then grew by 2.1% to -$280.3 million in 2024, then plummeted by 36.75% to -$383.3 million in 2025.
  • The last three reported values for Enterprise Value were -$383.3 million (Q4 2025), -$375.5 million (Q3 2025), and -$304.6 million (Q2 2025) per Business Quant data.